FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma By Ogkologos - July 22, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-022 study Source RELATED ARTICLESMORE FROM AUTHOR How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... MOST POPULAR FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for... January 24, 2025 How I’m Working to Erase the Stigma of Lung Cancer: A... November 22, 2023 New on NCI’s Websites for January 2020 January 2, 2020 New Research in Treating Lymphoma and Improving Equity in Cancer Clinical... February 3, 2022 Load more HOT NEWS Using a Blood Test to Select Treatments for Advanced Gastrointestinal Stromal... Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative... EMA Recommends Granting a Marketing Authorisation for Generic Enzalutamide Duration of Bevacizumab Maintenance of 15 Months Remains the Standard in...
